Strategic Partnerships Zenas BioPharma has actively pursued collaborations and partnerships to advance its pipeline, including a May 13 2026 deal with Innocarepharma for a novel IL-17AA/AF inhibitor. Sales opportunities exist in licensing, co-development, and commercialization partnerships with specialty biotechs and CROs focusing on autoimmune indications.

Late-stage Focus The company is advancing two late-stage candidates, obexelimab and orelabrutinib, indicating potential near-term demand for alliance discussions, joint ventures, or upfront funding in exchange for milestone-rich collaborations and regional rights.

Global Access As a clinical-stage global biopharma, Zenas seeks broad geographic development of its assets. There are opportunities to present regional market access, distribution, and commercialization partnerships, particularly in centers with strong autoimmune trial activity and payer interest.

Strategic Financing Recent high-profile funding activity, including a $300 million royalty-based facility with Royalty Pharma, signals readiness for structured deals around milestones and royalties. BD pitches could emphasize milestone-rich agreements, upfronts, and royalty streams tied to obexelimab and related programs.

Investor & Stakeholder Engagement Public disclosures show active investor engagement and events (neuro perspectives, biotech summits) with potential for sponsor-led briefings, clinical data discussions, and strategic showcases to attract potential co-development partners, lenders, and royalty buyers.